Tumor Ablation Market By Function (Automated/Robotic ablation, Conventional ablation devices), By Technology (Hyperthermic ablation, Radiofrequency ablation, Microwave ablation, Laser ablation, Ultrasound ablation, Cryoablation), By Application (Primary lung cancer, Metastatic diseases, Pain palliation), By End User (Hospitals, Oncology institutes, Diagnostic centres) and Geography     

Tumor Ablation Market size was estimated at USD 620.71 million in 2021, growing at a CAGR of 13.2% during the forecast period 2021-2027. Tumor ablation is a minimally invasive surgical method that enables treats solid tumors in which special probes are used to freeze or burn cancers without the usual surgery. The tumor ablation method is guided by the help of a CT scan, MRI Scan and ultrasound to locate and position the needle probe into the tumor which requires a tiny hole of 3mm diameter to introduce the probe. When the probe is within cancer it is attached to a generator that burns and freezes cancer. The most common cancers that are treated by this method are lung cancer, renal cancer, and liver cancer. Innovations in resources and technologies required in tumor ablation have provided ample opportunities for various pharma and electronics companies to work for the betterment of currently available technologies. Innovations such as high intensity focused ultrasound (HIFU), irreversible electroporation and image-guided procedures are rising demand for adaptation of tumor ablation. Moreover, increased focus on R&D investments, product developments, and launches, acquisitions, mergers, and collaborations are few strategies adopted by the players in the Tumor Ablation Market.

Key Developments:

In 2016, Medtronic launched Barrx360 express radiofrequency ablation balloon catheter to treat Barrett's oesophagus

In 2016 May, BTG Plc. has acquired Galil Medical, cryoablation systems, and needles manufacturer.